Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Shares Outstanding (2016 - 2025)

Organogenesis Holdings has reported Shares Outstanding over the past 10 years, most recently at $127.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $127.0 million for Q4 2025, changed 0.39% from a year ago — trailing twelve months through Dec 2025 was $127.0 million (changed 0.39% YoY), and the annual figure for FY2025 was $127.0 million, changed 0.39%.
  • Shares Outstanding for Q4 2025 was $127.0 million at Organogenesis Holdings, roughly flat from $126.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ORGO hit a ceiling of $132.6 million in Q3 2024 and a floor of $125.7 million in Q4 2024.
  • Median Shares Outstanding over the past 5 years was $129.9 million (2022), compared with a mean of $129.6 million.
  • Biggest five-year swings in Shares Outstanding: grew 21.69% in 2021 and later dropped 4.32% in 2025.
  • Organogenesis Holdings' Shares Outstanding stood at $128.7 million in 2021, then increased by 1.74% to $130.9 million in 2022, then increased by 0.3% to $131.3 million in 2023, then dropped by 3.7% to $126.5 million in 2024, then rose by 0.39% to $127.0 million in 2025.
  • The last three reported values for Shares Outstanding were $127.0 million (Q4 2025), $127.6 million (Q3 2025), and $126.9 million (Q2 2025) per Business Quant data.